| VICORE PHARMA HOLDING AB |
| Schweden |
| Gesundheit |
| SE0007577895 / A14W4W |
| 6Y4 (Frankfurt) |
| FRA:6Y4, ETR:6Y4, 6Y4:GR |
| - |
| https://vicorepharma.com/ |
|
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company based in Sweden, specializing in the development of innovative therapies targeting severe respiratory and fibrotic diseases, particularly through angiotensin II type 2 receptor agoni..
>Volltext.. |
| 340.4 Mio. EUR |
| 243.94 Mio. EUR |
| 0.32 Mio. EUR |
| -44.7 Mio. EUR |
| -43.65 Mio. EUR |
| -0.17 EUR |
| - |
| 34.71 Mio. EUR |
| -37.46 Mio. EUR |
| 12.52 |
| -41.58% |
| -51.09% |
| - |
| - |
| - |
| - |
| VICORE PHARMA |
| 07.07.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|